NCT07369505 2026-01-27
Sapu003 in Advanced mTOR-sensitive Solid Tumors
SAPU NANO (US) LLC
Phase 1 Recruiting
Clinical Trials
7 trialsNCT05477576 2026-01-20
ACTION-1
RayzeBio, Inc.
Phase 3 Recruiting
NCT04919226 2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3 Active not recruiting
NCT02973204 2021-04-28
Circulating Tumor Cells and Tumor DNA in HCC and NET
University of Aarhus
Completed
NCT01469572 2018-10-18
Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases
Emory University
Phase 1 Completed
NCT01864070 2014-07-22
Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT00363051 2013-05-10
Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy
Novartis
Phase 2 Completed